1. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University.
- Author
-
Airoldi M, Brando V, Giordano C, Gabriele P, Bussi M, and Cortesina G
- Subjects
- Adult, Aged, Carcinoma secondary, Cisplatin therapeutic use, Female, Humans, Italy, Male, Middle Aged, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma drug therapy, Neoplasm Recurrence, Local drug therapy, Salivary Gland Neoplasms drug therapy
- Abstract
Twenty-seven patients (17 males, 10 females; median age 59 years) with recurrent high-grade malignancies of major (22 cases) and minor (5 cases) salivary gland origin (10 adenoid cystic carcinomas, 9 adenocarcinomas, 4 poorly differentiated carcinomas, 1 mixed malignant tumor, 3 mucoepidermoid carcinomas) were treated by monochemotherapy--cisplatin (CDDP) in 8 cases, or adriamycin in 5 cases--or polychemotherapy--CDDP + epirubicin + 5-fluorouracil/cyclophosphamide in 9 cases or CDDP + 5-fluorouracil in 3 cases with mucoepidermoid carcinomas. In adenocarcinoma-like tumors, patients treated by polychemotherapy showed a better response (9.1% CR, 36.3% PR) than patients treated with monochemotherapy (no CR, 23% PR). Patients with local recurrence and adenocarcinoma exhibited a better response. Median response duration: 7.5 months after poly- and 4 after monochemotherapy. Median overall survival time was 8+ months (responders: 14+) in the polychemotherapy group and 5.5 (responders: 8) in the monochemotherapy group. In the 3 cases with mucoepidermoid carcinoma 1 patient achieved a PR (33.3%) and in 2 there was no change.
- Published
- 1994
- Full Text
- View/download PDF